Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2020-01-23 Regulatory Filings
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that HLS Therapeutics has filed a New Drug Submission (NDS) for PERSERIS in Canada. It discusses the drug, its approval status in the US, and the company's business focus. There are no financial statements, regulatory certifications, or detailed financial data. The document is an announcement of a regulatory submission and product development update, not a financial report, earnings release, or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial compliance. The content is best classified as a general regulatory or corporate announcement. Given the options, the closest fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or corporate announcements that do not fit other categories. The document length and content confirm it is not a brief report publication announcement or a certification. Confidence is high due to clear content type and absence of financial data.
2020-01-23 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing regulatory and commercial developments related to the drug Vascepa, including data protection granted by Health Canada, sales estimates, and launch timing. It does not contain financial statements, detailed financial analysis, or comprehensive reporting typical of annual or interim reports. It also does not include voting results, management changes, or legal proceedings. The content is primarily an update on product status and commercial expectations, typical of a Capital/Financing Update or general corporate announcement. Given the focus on regulatory approval and commercial launch with sales estimates, the best fitting category is Capital/Financing Update (CAP). The document length (6772 characters) and content support this classification with high confidence.
2020-01-06 English
News release - English.pdf
Regulatory Filings
2019-12-31 English
News release - English.pdf
Regulatory Filings
2019-11-15 English
News release - English.pdf
Regulatory Filings
2019-11-07 English
Interim MD&A - English.pdf
Regulatory Filings
2019-11-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.